Elevated viral restriction factor levels in cortical blood vessels in schizophrenia

Biological Psychiatry

Volumn 76, Issue 2, 2014, Pages 160-167

  Siegel, Benjamin I ^a   Sengupta, Elizabeth J ^a   Edelson, Jessica R ^a   Lewis, David A ^a   Volk, David W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

GABA; GAD67; IFITM; immune; inflammation; parvalbumin

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE 67; HALOPERIDOL; INTERLEUKIN 6; MEMBRANE PROTEIN; MESSENGER RNA; OLANZAPINE; PARVALBUMIN; PLACEBO; SOMATOSTATIN; UNCLASSIFIED DRUG; VIRAL RESTRICTION FACTOR INTERFERON INDUCED TRANSMEMBRANE PROTEIN; 4 AMINOBUTYRIC ACID RECEPTOR; BENZODIAZEPINE DERIVATIVE; DIFFERENTIATION ANTIGEN; LEU-13 ANTIGEN; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTRIBUTABLE RISK; BLOOD VESSEL; CAUSE OF DEATH; CELL TYPE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMULSION; FEMALE; GRAY MATTER; HUMAN; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; NERVE CELL; NONHUMAN; OPTICAL DENSITY; PIA MATER; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; YOUNG ADULT; ANIMAL; DRUG EFFECTS; GENETICS; MACACA FASCICULARIS; METABOLISM; MIDDLE AGED; VASCULARIZATION;

ADULT; ANIMALS; ANTIGENS, DIFFERENTIATION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; GABAERGIC NEURONS; HALOPERIDOL; HUMANS; MACACA FASCICULARIS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 84903303787     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2013.09.019     Document Type: Article

References (63)

1. S.M. Purcell, N.R. Wray, J.L. Stone, P.M. Visscher, M.C. O'Donovan, and P.F. Sullivan et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder Nature 460 2009 748 752
2. J. Shi, D.F. Levinson, J. Duan, A.R. Sanders, Y. Zheng, and I. Pe'er et al. Common variants on chromosome 6p22.1 are associated with schizophrenia Nature 460 2009 753 757
3. H. Stefansson, R.A. Ophoff, S. Steinberg, O.A. Andreassen, S. Cichon, and D. Rujescu et al. Common variants conferring risk of schizophrenia Nature 460 2009 744 747
4. P. Jia, L. Wang, H.Y. Meltzer, and Z. Zhao Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data Schizophr Res 122 2010 38 42
5. S. Ripke, A.R. Sanders, K.S. Kendler, D.F. Levinson, P. Sklar, and P.A. Holmans et al. Genome-wide association study identifies five new schizophrenia loci Nat Genet 43 2011 969 976
6. A.S. Brown, M.D. Begg, S. Gravenstein, C.A. Schaefer, R.J. Wyatt, and M. Bresnahan et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia Arch Gen Psychiatry 61 2004 774 780
7. A.S. Brown, C.A. Schaefer, C.P. Quesenberry Jr, L. Liu, V.P. Babulas, and E.S. Susser Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring Am J Psychiatry 162 2005 767 773
8. A.S. Brown, J. Hooton, C.A. Schaefer, H. Zhang, E. Petkova, and V. Babulas et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring Am J Psychiatry 161 2004 889 895
9. A.S. Brown, and E.J. Derkits Prenatal infection and schizophrenia: A review of epidemiologic and translational studies Am J Psychiatry 167 2010 261 280
10. S. Potvin, E. Stip, A.A. Sepehry, A. Gendron, R. Bah, and E. Kouassi Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review Biol Psychiatry 63 2008 801 808
11. B.J. Miller, P. Buckley, W. Seabolt, A. Mellor, and B. Kirkpatrick Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects Biol Psychiatry 70 2011 663 671
12. M. Di Nicola, A. Cattaneo, N. Hepgul, M. Di Forti, K.J. Aitchison, and L. Janiri et al. Serum and gene expression profile of cytokines in first-episode psychosis Brain Behav Immun 31 2013 90 95
13. S.G. Fillman, N. Cloonan, V.S. Catts, L.C. Miller, J. Wong, and T. McCrossin et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia Mol Psychiatry 18 2013 206 214
14. D. Arion, T. Unger, D.A. Lewis, P. Levitt, and K. Mirnics Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia Biol Psychiatry 62 2007 711 721
15. P. Saetre, L. Emilsson, E. Axelsson, J. Kreuger, E. Lindholm, and E. Jazin Inflammation-related genes up-regulated in schizophrenia brains BMC Psychiatry 7 2007 46
16. M.S. Diamond, and M. Farzan The broad-spectrum antiviral functions of IFIT and IFITM proteins Nat Rev Immunol 13 2013 46 57
17. A.L. Brass, I.C. Huang, Y. Benita, S.P. John, M.N. Krishnan, and E.M. Feeley et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus Cell 139 2009 1243 1254
18. E.M. Feeley, J.S. Sims, S.P. John, C.R. Chin, T. Pertel, and L.M. Chen et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry PLoS Pathog 7 2011 e1002337
19. I.C. Huang, C.C. Bailey, J.L. Weyer, S.R. Radoshitzky, M.M. Becker, and J.J. Chiang et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus PLoS Pathog 7 2011 e1001258
20. J. Lu, Q. Pan, L. Rong, W. He, S.L. Liu, and C. Liang The IFITM proteins inhibit HIV-1 infection J Virol 85 2011 2126 2137
21. Y.K. Chan, I.C. Huang, and M. Farzan IFITM proteins restrict antibody-dependent enhancement of dengue virus infection PLoS One 7 2012 e34508
22. K. Li, R.M. Markosyan, Y.M. Zheng, O. Golfetto, B. Bungart, and M. Li et al. IFITM proteins restrict viral membrane hemifusion PLoS Pathog 9 2013 e1003124
23. C.C. Bailey, I.C. Huang, C. Kam, and M. Farzan Ifitm3 limits the severity of acute influenza in mice PLoS Pathog 8 2012 e1002909
24. K. Takao, K. Kobayashi, H. Hagihara, K. Ohira, H. Shoji, and S. Hattori et al. Deficiency of schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia Neuropsychopharm 38 2013 1409 1425
25. S. Akbarian, J.J. Kim, S.G. Potkin, J.O. Hagman, A. Tafazzoli, and W.E. Bunney Jr et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics Arch Gen Psychiatry 52 1995 258 266
26. D.W. Volk, M.C. Austin, J.N. Pierri, A.R. Sampson, and D.A. Lewis Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia Arch Gen Psychiatry 57 2000 237 245
27. 67) expression in schizophrenia and bipolar disorder Arch Gen Psychiatry 57 2000 1061 1069
28. M.P. Vawter, J.M. Crook, T.M. Hyde, J.E. Kleinman, D.R. Weinberger, and K.G. Becker et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: A preliminary study Schizophr Res 58 2002 11 20
29. T. Hashimoto, D.W. Volk, S.M. Eggan, K. Mirnics, J.N. Pierri, and Z. Sun et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia J Neurosci 23 2003 6315 6326
30. R.E. Straub, B.K. Lipska, M.F. Egan, T.E. Goldberg, J.H. Callicott, and M.B. Mayhew et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression Mol Psychiatry 12 2007 854 869
31. N. Mellios, H.S. Huang, S.P. Baker, M. Galdzicka, E. Ginns, and S. Akbarian Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia Biol Psychiatry 65 2009 1006 1014
32. M. Beneyto, A. Abbott, T. Hashimoto, and D.A. Lewis Lamina-specific alterations in cortical GABAA receptor subunit expression in schizophrenia Cereb Cortex 21 2011 999 1011
33. A.A. Curley, D. Arion, D.W. Volk, J.K. Asafu-Adjei, A.R. Sampson, and K.N. Fish et al. Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: Clinical, protein, and cell type-specific features Am J Psychiatry 168 2011 921 929
34. C.E. Duncan, M.J. Webster, D.A. Rothmond, S. Bahn, M. Elashoff, and W.C. Shannon Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia J Psychiatry Res 44 2010 673 681
35. S.J. Fung, S. Sivagnanasundaram, and C.S. Weickert Lack of change in markers of presynaptic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients Biol Psychiatry 69 2011 71 79
36. J.R. Glausier, and D.A. Lewis Selective pyramidal cell reduction of GABA(A) receptor alpha1 subunit messenger RNA expression in schizophrenia Neuropsychopharm 36 2011 2103 2110
37. D.W. Volk, T. Matsubara, S. Li, E.J. Sengupta, D. Georgiev, and Y. Minabe et al. Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia Am J Psychiatry 169 2012 1082 1091
38. Hoftman GD, Volk DW, Bazmi HH, Li S, Sampson AR, Lewis DA (in press): Altered cortical expression of GABA-related genes in schizophrenia: Evidence for incomplete developmental trajectories. Schizophr Bull.
39. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed 1994 American Psychiatric Association Washington, DC
40. D.W. Volk, S.M. Eggan, and D.A. Lewis Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia Am J Psychiatry 167 2010 1489 1498
41. D.W. Volk, P.V. Radchenkova, E.M. Walker, E.J. Sengupta, and D.A. Lewis Cortical opioid markers in schizophrenia and across postnatal development Cereb Cortex 22 2011 1215 1223
42. T. Hashimoto, H.H. Bazmi, K. Mirnics, Q. Wu, A.R. Sampson, and D.A. Lewis Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia Am J Psychiatry 165 2008 479 489
43. J. Vandesompele, K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, and A. De Paepe et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 3 34 2002 1 34 11
44. D.W. Volk, B.I. Siegel, C.D. Verrico, and D.A. Lewis Endocannabinoid metabolism in the prefrontal cortex in schizophrenia Schizophr Res 147 2013 53 57
45. H.M. Morris, T. Hashimoto, and D.A. Lewis Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder Cereb Cortex 18 2008 1575 1587
46. M. Beneyto, H.M. Morris, K.C. Rovensky, and D.A. Lewis Lamina- and cell-specific alterations in cortical somatostatin receptor 2 mRNA expression in schizophrenia Neuropharmacology 62 2012 1598 1605
47. K.A. Dorph-Petersen, J.N. Pierri, J.M. Perel, Z. Sun, A.R. Sampson, and D.A. Lewis The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys Neuropsychopharm 30 2005 1649 1661
48. M.M. Behrens, S.S. Ali, and L.L. Dugan Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia J Neurosci 28 2008 13957 13966
49. I.L. Campbell, C.R. Abraham, E. Masliah, P. Kemper, J.D. Inglis, and M.B. Oldstone et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6 Proc Natl Acad Sci U S A 90 1993 10061 10065
50. C.J. Heyser, E. Masliah, A. Samimi, I.L. Campbell, and L.H. Gold Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain Proc Natl Acad Sci U S A 94 1997 1500 1505
51. H. Samland, S. Huitron-Resendiz, E. Masliah, J. Criado, S.J. Henriksen, and I.L. Campbell Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6 J Neurosci Res 73 2003 176 187
52. D. Ibi, T. Nagai, A. Nakajima, H. Mizoguchi, T. Kawase, and D. Tsuboi et al. Astroglial IFITM3 mediates neuronal impairments following neonatal immune challenge in mice Glia 61 2013 679 693
53. U. Meyer, M. Nyffeler, A. Engler, A. Urwyler, M. Schedlowski, and I. Knuesel et al. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology J Neurosci 26 2006 4752 4762
54. G. Arrode-Bruses, and J.L. Bruses Maternal immune activation by poly(I:C) induces expression of cytokines IL-1beta and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain J Neuroinflammation 9 2012 83
55. D.B. Oskvig, A.G. Elkahloun, K.R. Johnson, T.M. Phillips, and M. Herkenham Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response Brain Behav Immun 26 2012 623 634
56. A. Basta-Kaim, E. Szczesny, M. Leskiewicz, K. Glombik, J. Slusarczyk, and B. Budziszewska et al. Maternal immune activation leads to age-related behavioral and immunological changes in male rat offspring - the effect of antipsychotic drugs Pharmacol Rep 64 2012 1400 1410
57. U. Meyer, M. Nyffeler, B.K. Yee, I. Knuesel, and J. Feldon Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice Brain Behav Immun 22 2008 469 486
58. J. Richetto, F. Calabrese, M.A. Riva, and U. Meyer Prenatal immune activation induces maturation-dependent alterations in the prefrontal GABAergic transcriptome [published online ahead of print January 17] Schizophr Bull 2013
59. B. Tang, H. Jia, R.J. Kast, and E.A. Thomas Epigenetic changes at gene promoters in response to immune activation in utero Brain Behav Immun 30 2013 168 175
60. S. Akhondzadeh, M. Tabatabaee, H. Amini, S.A. Ahmadi Abhari, S.H. Abbasi, and B. Behnam Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial Schizophr Res 90 2007 179 185
61. N. Muller, D. Krause, S. Dehning, R. Musil, R. Schennach-Wolff, and M. Obermeier et al. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment Schizophr Res 121 2010 118 124
62. M. Pesu, A. Laurence, N. Kishore, S.H. Zwillich, G. Chan, and J.J. O'Shea Therapeutic targeting of Janus kinases Immunol Rev 223 2008 132 142
63. A. Deisseroth, E. Kaminskas, J. Grillo, W. Chen, H. Saber, and H.L. Lu et al. U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis Clin Cancer Res 18 2012 3212 3217